Loading
Cancer biologist who directs the NCI-designated Salk Cancer Center in La Jolla and holds the William R. Brody Chair at the Salk Institute.
Reuben Shaw is Director of the NCI-designated Salk Cancer Center and a professor in the Molecular and Cell Biology Laboratory at the Salk Institute for Biological Studies, where he holds the William R. Brody Chair. His laboratory studies how cancer and metabolic diseases such as type 2 diabetes share biochemical pathways, centred on the AMPK pathway and its regulation by the tumour suppressor LKB1, which led him to test whether metabolic drugs such as metformin could be used against cancer. He trained at Cornell (BS), MIT (PhD) and Harvard Medical School (postdoctoral), and received a Howard Hughes Medical Institute Early Career Scientist award in 2009 and a National Cancer Institute Outstanding Investigator Award in 2017.
| Title | Journal | Year |
|---|---|---|
| The LKB1–AMPK pathway: metabolism and growth control in tumour suppression | Nature Reviews Cancer | 2009 |
| Tumor Suppression by LKB1: SIK-ness Prevents Metastasis | Science Signaling | 2009 |
| Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models | Nature Medicine | 2016 |
Shares Howard Hughes Medical Institute and the tags leadership, clinician-scientist, research-institute.
Shares the tags leadership, clinician-scientist, research-institute.
Shares the tags leadership, clinician-scientist, research-institute.
Shares the tags leadership, clinician-scientist, research-institute.
Shares the tags leadership, clinician-scientist, research-institute.
Shares the tags leadership, clinician-scientist, research-institute.
Shares the tags leadership, clinician-scientist, research-institute.
Shares the tags leadership, clinician-scientist, research-institute.